1.Arbuckle, MR et al. (2003) Development of autoantibodies before the clinical onset of systemic lupus erythematosus. The New England Journal of Medicine 349, 1526–1533.
2.Satoh, M et al. (2012) Prevalence and sociodemographic correlates of antinuclear antibodies in the United States. Arthritis and Rheumatism 64, 2319–2327.
3.Hasni, SA (2012) Role of Helicobacter pylori infection in autoimmune diseases. Current Opinion in Rheumatology 24, 429–434.
4.Miller, FW (2011) Environmental agents and autoimmune diseases. Advances in Experimental Medicine and Biology 711, 61–81.
5.Grad, YH, Lipsitch, M and Aiello, AE (2012) Secular trends in Helicobacter pylori seroprevalence in adults in the United States: evidence for sustained race/ethnic disparities. American Journal of Epidemiology 175, 54–59.
6.Pounder, RE and Ng, D (1995) The prevalence of Helicobacter pylori infection in different countries. Alimentary Pharmacology & Therapeutics 9(suppl. 2), 33–39.
7.McColl, KE (2010) Clinical practice. Helicobacter pylori infection. The New England Journal of Medicine 362, 1597–1604.
8.Lina, TT et al. (2014) Immune evasion strategies used by Helicobacter pylori. World Journal of Gastroenterology 20, 12753–12766.
9.Curtin, LR et al. (2012) The National Health and Nutrition Examination Survey: sample design, 1999–2006. Vital Health Statistics 2, 1–39.
11.Centers for Disease Control and Prevention. National Health and Nutrition Examination Survey 1999–2001 Data Documentation, Codebook, and Frequencies: Autoantibodies – Immunofluorescence & Immunoprecipitation Analyses. Available at https://wwwn.cdc.gov/Nchs/Nhanes/1999-2000/SSANA_A.htm (Accessed 5 November 2018).
12.Meier, HCS et al. (2016) Early life socioeconomic position and immune response to persistent infections among elderly Latinos. Social Science & Medicine 166, 77–85.
13.Bobak, M et al. (2000) Own education, current conditions, parental material circumstances, and risk of myocardial infarction in a former communist country. Journal of Epidemiology and Community Health 54, 91–96.
14.Dinse, GE et al. (2018) Prescription medication use and antinuclear antibodies in the United States, 1999–2004. Journal of Autoimmunity 92, 93–103.
15.Rao, JNK and Scott, AJ (1987) On simple adjustments to chi-squared tests with survey data. Annals of Statistics 5, 385–397.
16.Kuwana, M (2014) Helicobacter pylori-associated immune thrombocytopenia: clinical features and pathogenic mechanisms. World Journal of Gastroenterology 20, 714–723.
17.Basso, D et al. (2000) Antigastric autoantibodies in Helicobacter pylori infection: role in gastric mucosal inflammation. International Journal of Clinical Laboratory Research 30, 173–178.
18.Faller, G et al. (2000) Mucosal production of antigastric autoantibodies in Helicobacter pylori gastritis. Helicobacter 5, 129–134.
19.Ram, M et al. (2013) Helicobacter pylori serology in autoimmune diseases – fact or fiction? Clinical Chemistry and Laboratory Medicine 51, 1075–1082.
20.Amedei, A et al. (2003) Molecular mimicry between Helicobacter pylori antigens and H+, K+–adenosine triphosphatase in human gastric autoimmunity. Journal of Experimental Medicine 198, 1147–1156.
21.Alvarez-Arellano, L and Maldonado-Bernal, C (2014) Helicobacter pylori and neurological diseases: married by the laws of inflammation. World Journal of Gastrointestinal Pathophysiology 5, 400–404.
22.Wandl, UB et al. (1992) Lupus-like autoimmune disease induced by interferon therapy for myeloproliferative disorders. Clinical Immunology and Immunopathology 65, 70–74.
23.Frydman, GH et al. (2015) Helicobacter pylori eradication in patients with immune thrombocytopenic purpura: a review and the role of biogeography. Helicobacter 20, 239–251.
24.Vanegas, YAM and Vishnu, P (2019) Management of Helicobacter pylori in patients with immune thrombocytopenia. Hamostaseologie 39, 279–283.